The market slammed GRAIL before the opening bell. The stock closed at US$74.18 and now sits near US$63, a 14% one day hit that signals frustration with the latest quarter. However, the headline from the earnings release is not a collapse in the business. GRAIL delivered Q2 2026 revenue of US$44.7m and more than 61,000 Galleri tests, while the company still reported a net loss of US$110.2m. The selloff appears to be about patience. Investors are taking a hard look at how long they are willing to wait for this revenue story to outweigh the losses.

Impressed by GRAIL’s growing test volumes but worried about the ongoing losses and cash burn risk? Consider using our screener of 78 resilient stocks with low risk scores to benchmark GRAIL against companies that have steadier finances and clearer paths to profitability.

Q2 2026 Earnings Summary

• Revenue (Q2 2026 vs. Q2 2025): US$44.7m vs. US$35.5m (an increase of about 26%)
• Net Loss (Q2 2026 vs. Q2 2025): US$110.2m loss vs. US$114.0m loss (the loss narrowed by about 3%)
• Basic EPS (Q2 2026 vs. Q2 2025): loss of US$2.56 per share vs. loss of US$3.18 per share (per share loss improved by about 20%)
• Galleri Test Volume (Q2 2026 vs. Q2 2025): more than 61,000 tests compared with prior year quarter volume implied to be about 35% lower (management cited test volume growth of about 35% year on year)

Prefer clean visual charts instead of scrolling through extensive earnings tables and raw figures? See GRAIL’s full financial picture, with an emphasis on its path toward profitability, in the company report for GRAIL.

Evaluating GRAIL’s Growth-First Bull Story

The bullish pitch on GRAIL is that Galleri volume growth, richer clinical data and regulatory progress can eventually turn a loss-making model into a durable screening business. Q2 gives some support to that view. Screening revenue of US$42.6m and more than 61,000 tests show that physicians and employers are still ordering Galleri after the NHS trial setback and class action headlines. H1 test revenue above US$80m with 117,000 tests points to consistent throughput rather than a one-off spike.

The thesis also leans heavily on operating leverage rather than near term profit. Adjusted gross profit of US$21.6m improved as volumes climbed, which is an important milestone for any high fixed cost diagnostics platform. The completed sales force build and the Samsung equity deal, which lifted cash to US$861.6m, fit with a narrative of investing ahead of a potential FDA advisory committee and eventual Medicare coverage discussions.

See how GRAIL’s internal progress on Galleri volumes, gross profit and cash on hand compares with external expectations by reviewing where the street has set its targets. Then compare that growth-first story with the consensus price target analysis for GRAIL.

Bear Case on GRAIL’s Cash Burn Looks More Credible

The bearish view is that GRAIL’s cash burn, legal overhang and uncertain reimbursement path could outweigh Galleri’s test growth for a long time. Q2 does not put that fear to rest. Revenue and volumes moved up, yet adjusted EBITDA loss widened to US$90.3m and net loss was US$110.2m. That signals the completed sales build is not yet translating into operating leverage. Management highlighted a US$861.6m cash balance, helped by the US$110m Samsung investment, but this is still funding sizeable quarterly losses while broad payer coverage remains unresolved.

Bears also worry that legal and regulatory setbacks will drag on sentiment and capital access. The stock fell a further 14.5% after earnings and multiple class actions linked to the NHS Galleri miss are still live, with the lead plaintiff deadline only just passed on 4 August 2026. This print keeps those concerns very much alive.

Expose whether GRAIL’s widening losses, shareholder dilution and legal overhang are early warnings of deeper structural problems by reviewing our risk analysis for GRAIL which shows 3 important warning signs.

Stay Ahead With GRAIL And Simply Wall St

If the sharp move in GRAIL after its latest earnings has your attention, register for free with Simply Wall St and add it to your Watchlist to track the share price against fair value and watch how the thesis develops. Once you decide to take a position, keep on top of the story with the Portfolio Command Center that highlights only the most important updates on your holdings. For a longer term view, use the Community to see how other investors are thinking about GRAIL and similar stocks. This can help you identify potential catalysts and risks early so you can stay a step ahead of the market.

Seeking Alternatives Beyond GRAIL?

Fresh stock ideas can move quickly once the crowd catches on. Scan for potential breakouts and momentum shifts while the data is still under the radar for now. Act now.

• Spot companies building future infrastructure early and run through 36 power grid technology and infrastructure stocks before momentum increases and the best entry points start dropping out of reach.
• Hunt for potential cash generators and track 69 profitable AI stocks that aren't just burning cash while these AI opportunities still trade under the radar and before enthusiasm sends valuations into a full breakout.
• Zero in on potential compounded resilience and review the list of solid balance sheet and fundamentals stocks (49 results) so you are not caught chasing quality stocks after the crowd has moved.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.